Comparar compuestos
Seleccione hasta 3 compuestos para comparar protocolos, mecanismos, criterios de valoración y hallazgos de seguridad en paralelo.
Peptijournal · Cagrilintide vs Retatrutide · https://peptijournal.com/compare?c=cagrilintide,retatrutide · Impreso
01Protocol
Cagrilintide
- Viales
- 5 mg
- Datos de dosis
- Referencia de laboratorio; no indicado
Retatrutide
- Start
- 2 mg
- Range
- 2–12 mg
- Frequency
- Once weekly
- Cycle
- Ongoing, titrated every 4 weeks
- Vials
- 10 / 20 / 30 mg
- Ajuste gradual
- Weeks 1–4: 2 mg
- Weeks 5–8: 4 mg
- Weeks 9–12: 8 mg
- Weeks 13+: 12 mg (highest trial arm)
02Quick calculator
Cagrilintide
Retatrutide
03Mechanism of action
Cagrilintide
Cagrilintide is a long-acting analogue of amylin, a pancreatic hormone that induces satiety. It is studied alone and combined with semaglutide (CagriSema).
Retatrutide
Retatrutide (LY3437943) is a single peptide agonist of three receptors: GIP, GLP-1 and glucagon. Adding glucagon-receptor activity is studied for increasing energy expenditure and liver-fat effects on top of the appetite effects of GIP/GLP-1 agonism.
04Study endpoints
Cagrilintide
- Phase 2 (26 weeks): every cagrilintide arm reduced weight more than placebo (6.0%–10.8% vs 3.0%); the top arm also beat liraglutide (10.8% vs 9.0%).
- Combination evidence, not cagrilintide-alone efficacy: REDEFINE 1 (3,417 adults without diabetes) reported −20.4% mean weight change with cagrilintide–semaglutide vs −3.0% with placebo at 68 weeks using the treatment-policy estimand.
- Combination evidence in type 2 diabetes: REDEFINE 2 reported −13.7% mean weight change with cagrilintide–semaglutide vs −3.4% with placebo at 68 weeks, not a standalone cagrilintide result.
Retatrutide
- Phase 2 obesity trial (338 adults): mean weight change at 48 weeks ranged from −8.7% to −24.2% across arms vs −2.1% with placebo.
- In the highest arm, 83% of participants lost 15% or more of body weight at 48 weeks, vs 2% on placebo.
- Preclinical and early clinical work describes glycaemic and weight effects from combined triple-receptor agonism.
05Safety & regulatory findings
Cagrilintide
- Investigational: not approved as a standalone medicine.
- Phase 2: gastrointestinal events in 41%–63% vs 32% on placebo, mainly nausea. REDEFINE 1 combination arm: gastrointestinal events in 79.6% vs 39.9% with placebo.
Retatrutide
- Investigational: not approved by the FDA or EMA for any indication. Phase 3 trials are ongoing.
- Phase 2 adverse events were mainly gastrointestinal and dose-related; heart-rate increases were also reported.